Copyright Reports & Markets. All rights reserved.

(Post-pandemic Era)-Global Lung Cancer Liquid Biopsy Market Segment Research Report 2022

Buy now

Table of Contents

    Global Lung Cancer Liquid Biopsy Market Segment Research Report 2022

      1. Research Scope

        2. Market Overview

        • 2.1 Product Introduction, Application, Picture
        • 2.2 Global Lung Cancer Liquid Biopsy Market by Value
          • 2.2.1 Global Lung Cancer Liquid Biopsy Revenue by Type
          • 2.2.2 Global Lung Cancer Liquid Biopsy Market by Value (%)
        • 2.3 Global Lung Cancer Liquid Biopsy Market by Production
          • 2.3.1 Global Lung Cancer Liquid Biopsy Production by Type
          • 2.3.2 Global Lung Cancer Liquid Biopsy Market by Production (%)

        3. The Major Driver of Lung Cancer Liquid Biopsy Industry

        • 3.1 Historical & Forecast Global Lung Cancer Liquid Biopsy Demand
        • 3.2 Largest Application for Lung Cancer Liquid Biopsy (2018-2028)
        • 3.3 The Major Downstream Company in China Market 2022

        4. Global and Regional Lung Cancer Liquid Biopsy Market

        • 4.1 Regional Market Size in Terms of Production & Demand (2022)
        • 4.2 Regional Market Share in Terms of Revenue (2018-2022)
        • 4.3 Concentration Ratio (CR5& CR10) of Lung Cancer Liquid Biopsy Market
        • 4.4 Mergers & Acquisitions, Expansion Plans

        5. US Lung Cancer Liquid Biopsy Production, Demand (2018-2028)

        • 5.1 Current and Estimated Production Breakdown by Type
        • 5.2 Current and Estimated Demand Breakdown by Type
        • 5.3 Current and Estimated Demand Breakdown by Application
        • 5.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 5.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        6. Europe Lung Cancer Liquid Biopsy Production, Demand (2018-2028)

        • 6.1 Current and Estimated Production Breakdown by Type
        • 6.2 Current and Estimated Demand Breakdown by Type
        • 6.3 Current and Estimated Demand Breakdown by Application
        • 6.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 6.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        7. China Lung Cancer Liquid Biopsy Production, Demand (2018-2028)

        • 7.1 Current and Estimated Production Breakdown by Type
        • 7.2 Current and Estimated Demand Breakdown by Type
        • 7.3 Current and Estimated Demand Breakdown by Application
        • 7.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 7.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        8. Japan Lung Cancer Liquid Biopsy Production, Demand (2018-2028)

        • 8.1 Current and Estimated Production Breakdown by Type
        • 8.2 Current and Estimated Demand Breakdown by Type
        • 8.3 Current and Estimated Demand Breakdown by Application
        • 8.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 8.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        9. India Lung Cancer Liquid Biopsy Production, Demand (2018-2028)

        • 9.1 Current and Estimated Production Breakdown by Type
        • 9.2 Current and Estimated Demand Breakdown by Type
        • 9.3 Current and Estimated Demand Breakdown by Application
        • 9.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 9.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        10. Korea Lung Cancer Liquid Biopsy Production, Demand (2018-2028)

        • 10.1 Current and Estimated Production Breakdown by Type
        • 10.2 Current and Estimated Demand Breakdown by Type
        • 10.3 Current and Estimated Demand Breakdown by Application
        • 10.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 10.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        11. Southeast Asia Lung Cancer Liquid Biopsy Production, Demand (2018-2028)

        • 11.1 Current and Estimated Production Breakdown by Type
        • 11.2 Current and Estimated Demand Breakdown by Type
        • 11.3 Current and Estimated Demand Breakdown by Application
        • 11.4 Current and Estimated Revenue Breakdown by Type (2018-2028)
        • 11.5 Current and Estimated Revenue Breakdown by Application (2018-2028)

        12. Global Lung Cancer Liquid Biopsy Average Price Trend

        • 12.1 Market Price for Each Type of Lung Cancer Liquid Biopsy in US (2018-2022)
        • 12.2 Market Price for Each Type of Lung Cancer Liquid Biopsy in Europe (2018-2022)
        • 12.3 Market Price for Each Type of Lung Cancer Liquid Biopsy in China (2018-2022)
        • 12.4 Market Price for Each Type of Lung Cancer Liquid Biopsy in Japan (2018-2022)
        • 12.5 Market Price for Each Type of Lung Cancer Liquid Biopsy in India (2018-2022)
        • 12.6 Market Price for Each Type of Lung Cancer Liquid Biopsy in Korea (2018-2022)
        • 12.7 Market Price for Each Type of Lung Cancer Liquid Biopsy in Southeast Asia (2018-2022)

        13. Industrial Chain (Impact of COVID-19)

        • 13.1 Lung Cancer Liquid Biopsy Industrial Chain Analysis
        • 13.2 Downstream
        • 13.3 Impact of COVID-19
        • 13.4 Post-pandemic Era
        • 13.5 Technology Trends of Lung Cancer Liquid Biopsy

        14. Lung Cancer Liquid Biopsy Competitive Landscape

        • 14.1 RainDanceTechnologies
          • 14.1.1 RainDanceTechnologies Company Profiles
          • 14.1.2 RainDanceTechnologies Product Introduction
          • 14.1.3 RainDanceTechnologies Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.1.4 Strategic initiatives
        • 14.2 Biocartis
          • 14.2.1 Biocartis Company Profiles
          • 14.2.2 Biocartis Product Introduction
          • 14.2.3 Biocartis Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.2.4 Strategic initiatives
        • 14.3 Qiagen
          • 14.3.1 Qiagen Company Profiles
          • 14.3.2 Qiagen Product Introduction
          • 14.3.3 Qiagen Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.3.4 Strategic initiatives
        • 14.4 Guardant Health
          • 14.4.1 Guardant Health Company Profiles
          • 14.4.2 Guardant Health Product Introduction
          • 14.4.3 Guardant Health Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.4.4 Strategic initiatives
        • 14.5 MDxHealth
          • 14.5.1 MDxHealth Company Profiles
          • 14.5.2 MDxHealth Product Introduction
          • 14.5.3 MDxHealth Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.5.4 Strategic initiatives
        • 14.6 Pathway Genomics
          • 14.6.1 Pathway Genomics Company Profiles
          • 14.6.2 Pathway Genomics Product Introduction
          • 14.6.3 Pathway Genomics Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.6.4 Strategic initiatives
        • 14.7 NeoGenomics Laboraories
          • 14.7.1 NeoGenomics Laboraories Company Profiles
          • 14.7.2 NeoGenomics Laboraories Product Introduction
          • 14.7.3 NeoGenomics Laboraories Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.7.4 Strategic initiatives
        • 14.8 Sysmex Inostics
          • 14.8.1 Sysmex Inostics Company Profiles
          • 14.8.2 Sysmex Inostics Product Introduction
          • 14.8.3 Sysmex Inostics Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.8.4 Strategic initiatives
        • 14.9 Cynvenio
          • 14.9.1 Cynvenio Company Profiles
          • 14.9.2 Cynvenio Product Introduction
          • 14.9.3 Cynvenio Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.9.4 Strategic initiatives
        • 14.10 Menarini Silicon Biosystems
          • 14.10.1 Menarini Silicon Biosystems Company Profiles
          • 14.10.2 Menarini Silicon Biosystems Product Introduction
          • 14.10.3 Menarini Silicon Biosystems Lung Cancer Liquid Biopsy Sales, Revenue (2018-2022)
          • 14.10.4 Strategic initiatives
        • 14.11 Adaptive Biotechnologies
        • 14.12 Biocept
        • 14.13 Angle plc

        15. Conclusion

          16. Methodology and Data Source

          Summary

          The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.

          2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.

          According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.

          Beijing Yanjing Bizhi Information Consulting Co., Ltd. (XYZResearch)released the 《(Post-pandemic Era)-Global Lung Cancer Liquid Biopsy Market Segment Research Report 2022》, which aims to sort out the development status and trends of the Lung Cancer Liquid Biopsy industry at home and abroad, estimate the overall market scale of the Lung Cancer Liquid Biopsy industry and the market share of major countries, Lung Cancer Liquid Biopsy industry, and study and judge the downstream market demand of Lung Cancer Liquid Biopsy through systematic research, Analyze the competition pattern of Lung Cancer Liquid Biopsy, so as to help solve the pain points of various stakeholders in Lung Cancer Liquid Biopsy industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.

          Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Lung Cancer Liquid Biopsy Market by XYZResearch Include
          USA
          Europe
          China
          Japan
          India
          Korea
          Southeast Asia
          Competitive Analysis; Who are the Major Players in Lung Cancer Liquid Biopsy Market?
          RainDanceTechnologies
          Biocartis
          Qiagen
          Guardant Health
          MDxHealth
          Pathway Genomics
          NeoGenomics Laboraories
          Sysmex Inostics
          Cynvenio
          Menarini Silicon Biosystems
          Adaptive Biotechnologies
          Biocept
          Angle plc
          Major Type of Lung Cancer Liquid Biopsy Covered in XYZResearch report:
          Exosomes and RNA
          CTCs and ctDNA
          Application Segments Covered in XYZResearch Market
          Hospitals
          Clinics
          Others

          For any other requirements, please feel free to contact us and we will provide you customized report.

          Buy now